Literature DB >> 21862343

Hepatic FXR: key regulator of whole-body energy metabolism.

João Soeiro Teodoro1, Anabela Pinto Rolo, Carlos Marques Palmeira.   

Abstract

The farnesoid X receptor (FXR) is a nuclear receptor whose activation leads to alterations in pathways involved in energy metabolism. For example, it serves as a bile acid receptor in tissues such as the liver, and as an energy metabolism regulator in liver, muscle and adipose tissue. However, the effects of FXR activation are not exclusive to the tissue where it is present, because receptor crosstalk affects tissues throughout the body. It has been demonstrated that FXR regulates the metabolism of not just bile acids, but also of fats and hydrocarbon metabolites. FXR is currently under study as a therapeutic target for the treatment of diseases of excess, such as diabetes. Here we review the effects of FXR activation in the response of an organism to excess energy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862343     DOI: 10.1016/j.tem.2011.07.002

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  42 in total

1.  The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin.

Authors:  Miao Hu; Sandra S H Lui; Lai-Shan Tam; Edmund K Li; Brian Tomlinson
Journal:  J Lipid Res       Date:  2012-04-24       Impact factor: 5.922

Review 2.  Does bariatric surgery improve adipose tissue function?

Authors:  H Frikke-Schmidt; R W O'Rourke; C N Lumeng; D A Sandoval; R J Seeley
Journal:  Obes Rev       Date:  2016-06-08       Impact factor: 9.213

Review 3.  The significance of the nuclear farnesoid X receptor (FXR) in β cell function.

Authors:  Martina Düfer; Katrin Hörth; Peter Krippeit-Drews; Gisela Drews
Journal:  Islets       Date:  2012-09-01       Impact factor: 2.694

Review 4.  MicroRNAs in biliary diseases.

Authors:  Patricia Munoz-Garrido; Maite García-Fernández de Barrena; Elizabeth Hijona; Miguel Carracedo; José J G Marín; Luis Bujanda; Jesús M Banales
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

5.  Supplementation with an insoluble fiber obtained from carob pod (Ceratonia siliqua L.) rich in polyphenols prevents dyslipidemia in rabbits through SIRT1/PGC-1α pathway.

Authors:  María Valero-Muñoz; Sandra Ballesteros; Baltasar Ruiz-Roso; Lourdes Pérez-Olleros; Beatriz Martín-Fernández; Vicente Lahera; Natalia de Las Heras
Journal:  Eur J Nutr       Date:  2017-12-22       Impact factor: 5.614

6.  Depletion of hepatic forkhead box O1 does not affect cholelithiasis in male and female mice.

Authors:  Xiaoyun Feng; Cuiling Zhu; Sojin Lee; Jingyang Gao; Ping Zhu; Jun Yamauchi; Chenglin Pan; Sucha Singh; Shen Qu; Rita Miller; Satdarshan P Monga; Yongde Peng; H Henry Dong
Journal:  J Biol Chem       Date:  2020-04-09       Impact factor: 5.157

7.  Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations.

Authors:  Edithe Selwa; Eddy Elisée; Agustin Zavala; Bogdan I Iorga
Journal:  J Comput Aided Mol Des       Date:  2017-09-02       Impact factor: 3.686

Review 8.  Gastrointestinal metabolic surgery for the treatment of type 2 diabetes mellitus.

Authors:  Eng-Hong Pok; Wei-Jei Lee
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 9.  Farnesoid X receptor alpha (FXRα) is a critical actor of the development and pathologies of the male reproductive system.

Authors:  Manon Garcia; Laura Thirouard; Mélusine Monrose; Hélène Holota; Angélique De Haze; Françoise Caira; Claude Beaudoin; David H Volle
Journal:  Cell Mol Life Sci       Date:  2019-08-12       Impact factor: 9.261

Review 10.  Bile acids: emerging role in management of liver diseases.

Authors:  Amon Asgharpour; Divya Kumar; Arun Sanyal
Journal:  Hepatol Int       Date:  2015-08-29       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.